ARCHIVES

NCI, FDA Are Feuding Again, This Time Overcharge That DCT Moved Too Slowly On Toxicity Notification

This article is from The Cancer Letter archive.

Vol. 07 No. 15 | April 10, 1981

Download PDF Visit The Full Archive

Related Articles

In Brief: Cancer Program “Strengthened” NIH, Report From Biomedical Research Panel Contends

April 16, 1976

Estrogen Can Benefit Women With Metastatic Breast Cancer

January 30, 2009

Large Phase III Trial Seeks Optimal Use Of Tykerb vs. Herceptin In Breast Cancer

February 29, 2008

Waxman Adds NIH Bypass Budget To Authorization Bill, OKs$1.32 Billion for NCI In FY 1984

April 1, 1983

NCI Advises Five-Year Limit On Tamoxifen Use, in Letter To Doctors

December 8, 1995

Conte To Introduce Bill To Stem Loss Of NIH “Superstars”

March 31, 1989